

Amedeo De NicolÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254973/publications.pdf>

Version: 2024-02-01

99
papers

1,770
citations

304743

22
h-index

315739

38
g-index

99
all docs

99
docs citations

99
times ranked

2759
citing authors

#	ARTICLE	IF	CITATIONS
1	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020, 12, 1359.	4.1	337
2	A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 369-375.	2.8	115
3	Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect. <i>Bioanalysis</i> , 2017, 9, 1093-1105.	1.5	69
4	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	3.0	69
5	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 40-51.	2.8	67
6	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 70, 143-149.	2.4	59
7	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 223-230.	2.8	41
8	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 197-203.	2.4	40
9	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 535-541.	2.8	39
10	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2535-2543.	2.4	34
11	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 279-285.	2.8	33
12	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBV eAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015, 22, 318-327.	2.0	32
13	UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 127-132.	2.8	31
14	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 850-857.	2.0	31
15	An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 512-517.	2.8	29
16	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013, 100, 114-119.	4.1	27
17	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 66, 376-380.	2.8	26
18	A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 78-79, 217-223.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014, 21, 260-263.	2.0	24
20	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopurine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 271-278.	2.8	23
21	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 8-11.	2.8	23
22	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 913-925.	1.3	23
23	Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. <i>Neurocritical Care</i> , 2019, 31, 116-124.	2.4	23
24	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2014, 20, 335-341.	1.0	21
25	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016, 17, 925-941.	1.3	21
26	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 119-126.	2.8	20
27	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients.. <i>Journal of Mass Spectrometry</i> , 2017, 52, 187-195.	1.6	20
28	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 718-724.	2.8	20
29	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 826-827.	3.0	18
30	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017, 18, 651-661.	1.3	17
31	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 1083-1088.	1.9	17
32	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017, 5, 66.	3.2	17
33	Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4042-4047.	3.2	16
34	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 64-69.	2.8	16
35	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018, 19, 145-165.	1.3	16
36	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 47-55.	5.6	14

#	ARTICLE	IF	CITATIONS
37	Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg ⁺ negative and genotype A, D and E. <i>Journal of Medical Virology</i> , 2014, 86, 1845-1850.	5.0	13
38	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 63-69.	5.6	13
39	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014, 109, 7-14.	4.1	12
40	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 441.	2.0	12
41	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 164-172.	1.5	11
42	UPLC ⁻ MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 443-449.	2.8	11
43	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106.	4.7	11
44	Effect of <i>ABCC2</i> and <i>ABCG2</i> Gene Polymorphisms and CSF to α CS Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1550-1556.	2.0	11
45	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 657-661.	2.5	10
46	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 307-310.	1.5	10
47	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1659-1664.	3.0	10
48	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 615-620.	2.3	10
49	Identification of na^{\sim} ve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014, 106, 105-110.	4.1	9
50	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 171.	2.1	9
51	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1155-1160.	3.0	9
52	Influence of ABCB11 and HNF4 \pm genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2846-2849.	3.0	8
53	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-na [~] ve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 324-327.	2.5	7
54	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 22-27.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	2.4	7
56	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2021, 14, 12.	3.8	7
57	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 94, 29-35.	0.7	6
58	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 417-427.	2.0	6
59	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021, 11, 443.	3.3	6
60	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021, 9, 1288.	3.2	6
61	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018, 163, 961-967.	2.1	5
62	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 405-412.	1.6	5
63	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021, 8, 189.	2.4	5
64	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. <i>Frontiers in Pharmacology</i> , 2021, 12, 755184.	3.5	5
65	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2023, 192, 423-430.	1.5	5
66	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017, 18, 607-611.	1.3	4
67	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 965-968.	1.9	4
68	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018, 60, 42-47.	2.3	4
69	Antiretroviral concentrations in the presence and absence of valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1969-1971.	3.0	4
70	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106297.	2.5	4
71	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4432-4438.	2.4	4
72	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021, 14, 462.	3.8	4

#	ARTICLE	IF	CITATIONS
73	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 750433.	3.5	4
74	Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. <i>Journal of Hepatology</i> , 2014, 61, 178-179.	3.7	3
75	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017, 51, 167-172.	2.3	3
76	Correlation between Entecavir Penetration in Peripheral Blood Mononuclear Cells and HBV DNA Decay during Treatment of HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 373-377.	1.0	3
77	Pharmacokinetics of bicitegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3320-3322.	3.0	3
78	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021, 9, 1202.	3.2	3
79	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113337.	2.8	3
80	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017, 49, 705-708.	0.9	2
81	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 199-206.	1.5	2
82	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 202-204.	1.8	2
83	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	2
84	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021, 14, 460.	3.8	2
85	Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from "Integriamocia", a Pilot Pharmacokinetic Study. <i>Molecules</i> , 2022, 27, 1042.	3.8	2
86	Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis. <i>Journal of Chemotherapy</i> , 2022, 34, 416-418.	1.5	2
87	Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. <i>Archives of Virology</i> , 2022, 167, 1669-1674.	2.1	2
88	No pharmacokinetic interaction between raltegravir and amlodipine. <i>Aids</i> , 2014, 28, 1993-1995.	2.2	1
89	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. <i>Hypertension</i> , 2016, 67, e3-4.	2.7	1
90	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018, 19, 701-707.	1.3	1

#	ARTICLE	IF	CITATIONS
91	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. <i>Diagnostics</i> , 2021, 11, 869.	2.6	1
92	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022, 102, 154218.	5.3	1
93	A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4. <i>Intervirology</i> , 2016, 59, 283-284.	2.8	0
94	Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis. <i>Journal of Infection and Public Health</i> , 2020, 13, 315-316.	4.1	0
95	Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C. <i>Antiviral Therapy</i> , 2019, 24, 553-555.	1.0	0
96	Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. <i>International Journal of Pharmaceutical Compounding</i> , 2016, 20, 343-346.	0.0	0
97	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq1 1 0.784314 rgBT /Overlock	3.8	0
98	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0013622.	3.2	0
99	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022, 15, 630.	3.8	0